CGTX (Cognition Therapeutics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGTX Cognition Therapeutics Inc CGTX
34 GF Score
Price $0.92
! 1 Warning Sign
View Full Analysis

What is Cognition Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CGTX vs PTHS, BDTX, CBUS: Short Interest Comparison

For the Biotechnology subindustry, Cognition Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognition Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's Short Interest falls into.


CGTX
34GF Score
Cognition Therapeutics Inc CGTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cognition Therapeutics Business Description

Address 2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
34GF Score

Get the complete analysis for CGTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price